
Francisco Guarner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4335469/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Commentary on: prebiotic effects: metabolic and health benefits. British Journal of Nutrition, 2022, 127, 554-555.	1.2	7
2	Anti-Inflammatory Effect of an O-2-Substituted (1-3)-β-D-Glucan Produced by Pediococcus parvulus 2.6 in a Caco-2 PMA-THP-1 Co-Culture Model. International Journal of Molecular Sciences, 2022, 23, 1527.	1.8	5
3	Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations?. World Journal of Gastroenterology, 2022, 28, 1204-1219.	1.4	21
4	Macrogol: Evaluación de la percepción de efectividad y calidad de vida en individuos con estreñimiento. Ars Pharmaceutica, 2022, 63, 234-243.	0.1	0
5	Colonic bacterial diversity and dysbiosis in active microscopic colitis as compared to chronic diarrhoea and healthy controls: effect of polyethylene glycol after bowel lavage for colonoscopy. BMC Gastroenterology, 2022, 22, .	0.8	1
6	Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. Gastroenterology, 2021, 160, 206-218.e13.	0.6	89
7	Evaluation of an O2-Substituted (1–3)-β-D-Glucan, Produced by Pediococcus parvulus 2.6, in ex vivo Models of Crohn's Disease. Frontiers in Microbiology, 2021, 12, 621280.	1.5	5
8	Long-Term Safety and Efficacy of Prebiotic Enriched Infant Formula—A Randomized Controlled Trial. Nutrients, 2021, 13, 1276.	1.7	14
9	Differential Effects of Western and Mediterranean-Type Diets on Gut Microbiota: A Metagenomics and Metabolomics Approach. Nutrients, 2021, 13, 2638.	1.7	32
10	Microbiota intestinal y salud. GastroenterologÃa Y HepatologÃa, 2021, 44, 519-535.	0.2	21
11	Gut microbes and health. GastroenterologÃa Y HepatologÃa (English Edition), 2021, 44, 519-535.	0.0	8
12	Diet and the Gut Microbiota in the Adulthood. , 2021, , 39-39.		0
13	Dysbiosis and relapse-related microbiome in inflammatory bowel disease: A shotgun metagenomic approach. Computational and Structural Biotechnology Journal, 2021, 19, 6481-6489.	1.9	21
14	A Fermented Milk Product Containing B. lactis CNCM I-2494 Improves the Tolerance of a Plant-Based Diet in Patients with Disorders of Gut–Brain Interactions. Nutrients, 2021, 13, 4542.	1.7	1
15	Antibiotics as Major Disruptors of Gut Microbiota. Frontiers in Cellular and Infection Microbiology, 2020, 10, 572912.	1.8	352
16	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. GastroenterologÃa Y HepatologÃa (English) Tj ETQq0 0 0 rgB	st @ø erloc	k 30 Tf 50 1
17	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento. GastroenterologÃa Y HepatologÃa, 2020, 43, 649-658.	0.2	7

#	Article	IF	CITATIONS
19	Abdominal distension after eating lettuce: The role of intestinal gas evaluated in vitro and by abdominal CT imaging. Neurogastroenterology and Motility, 2019, 31, e13703.	1.6	11
20	Editorial: Next-Generation Probiotics: From Commensal Bacteria to Novel Drugs and Food Supplements. Frontiers in Microbiology, 2019, 10, 1973.	1.5	38
21	Reply. Gastroenterology, 2019, 156, 1223.	0.6	Ο
22	Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. Liver International, 2018, 38, 295-302.	1.9	12
23	Effects of Prebiotics vs a Diet Low in FODMAPs in Patients With Functional Gut Disorders. Gastroenterology, 2018, 155, 1004-1007.	0.6	88
24	Consenso mexicano sobre probióticos en gastroenterologÃa. Revista De GastroenterologÃa De México, 2017, 82, 156-178.	0.4	20
25	Metabolic adaptation of colonic microbiota to galactooligosaccharides: a proofâ€ofâ€conceptâ€study. Alimentary Pharmacology and Therapeutics, 2017, 45, 670-680.	1.9	39
26	A microbial signature for Crohn's disease. Gut, 2017, 66, 813-822.	6.1	657
27	Colonic gas homeostasis: Mechanisms of adaptation following HOSTâ€G904 galactooligosaccharide use in humans. Neurogastroenterology and Motility, 2017, 29, e13080.	1.6	27
28	Effect of Chicory-derived Inulin on Abdominal Sensations and Bowel Motor Function. Journal of Clinical Gastroenterology, 2017, 51, 619-625.	1.1	25
29	Towards standards for human fecal sample processing in metagenomic studies. Nature Biotechnology, 2017, 35, 1069-1076.	9.4	581
30	Crohn's Disease Disturbs the Immune Properties of Human Adipose-Derived Stem Cells Related to Inflammasome Activation. Stem Cell Reports, 2017, 9, 1109-1123.	2.3	49
31	Alteration of the serum microbiome composition in cirrhotic patients with ascites. Scientific Reports, 2016, 6, 25001.	1.6	55
32	Transcriptional interactions suggest niche segregation among microorganisms in the human gut. Nature Microbiology, 2016, 1, 16152.	5.9	56
33	MetaTrans: an open-source pipeline for metatranscriptomics. Scientific Reports, 2016, 6, 26447.	1.6	87
34	Effect of inulin and fructo-oligosaccharide on the prevention of acute radiation enteritis in patients with gynecological cancer and impact on quality-of-life: a randomized, double-blind, placebo-controlled trial. European Journal of Clinical Nutrition, 2016, 70, 170-174.	1.3	47
35	Transportome Profiling Identifies Profound Alterations in Crohn's Disease Partially Restored by Commensal Bacteria. Journal of Crohn's and Colitis, 2016, 10, 850-859.	0.6	21
36	Gut Microbiota Linked to Sexual Preference and HIV Infection. EBioMedicine, 2016, 5, 135-146.	2.7	328

#	Article	IF	CITATIONS
37	Galectinâ€4 interacts with the drug transporter human concentrative nucleoside transporter 3 to regulate its function. FASEB Journal, 2016, 30, 544-554.	0.2	11
38	Digestive Symptoms in Healthy People and Subjects With Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2015, 49, e64-e70.	1.1	21
39	The gut microbiome: What do we know?. Clinical Liver Disease, 2015, 5, 86-90.	1.0	6
40	Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Scientific Reports, 2015, 5, 12693.	1.6	248
41	The administration of probiotics and synbiotics in immune compromised adults: is it safe?. Beneficial Microbes, 2015, 6, 3-17.	1.0	76
42	Accumulative effect of food residues on intestinal gas production. Neurogastroenterology and Motility, 2015, 27, 1621-1628.	1.6	19
43	Su1071 Registry on the Management of Acute Diarrhea in Children: Observational Study in Daily Practice (REMAD 2). Gastroenterology, 2015, 148, S-399-S-400.	0.6	0
44	A review of the systematic review process and its applicability for use in evaluating evidence for health claims on probiotic foods in the European Union. Nutrition Journal, 2015, 14, 16.	1.5	41
45	Safety of probiotics and synbiotics in children under 18 years of age. Beneficial Microbes, 2015, 6, 615-630.	1.0	58
46	A Single Mutation in the Gene Responsible for the Mucoid Phenotype of Bifidobacterium animalis subsp. lactis Confers Surface and Functional Characteristics. Applied and Environmental Microbiology, 2015, 81, 7960-7968.	1.4	38
47	Short-Term Effect of Antibiotics on Human Gut Microbiota. PLoS ONE, 2014, 9, e95476.	1.1	272
48	Anal gas evacuation and colonic microbiota in patients with flatulence: effect of diet. Gut, 2014, 63, 401-408.	6.1	104
49	Microbiome Composition by Pyrosequencing in Mesenteric Lymph Nodes of Rats with CCl ₄ -Induced Cirrhosis. Journal of Innate Immunity, 2014, 6, 263-271.	1.8	19
50	Effect of a lowâ€flatulogenic diet in patients with flatulence and functional digestive symptoms. Neurogastroenterology and Motility, 2014, 26, 779-785.	1.6	24
51	Coping With Common Gastrointestinal Symptoms in the Community. Journal of Clinical Gastroenterology, 2014, 48, 567-578.	1.1	35
52	From Basic to Applied Research. Journal of Clinical Gastroenterology, 2014, 48, S3-S4.	1.1	12
53	OP022 Low microbial gene diversity and depletion of Akkermansia muciniphila is associated with a relapsing course of ulcerative colitis. Journal of Crohn's and Colitis, 2014, 8, S12-S13.	0.6	1
54	The gut microbiota era marches on. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 647-649.	8.2	17

#	Article	IF	CITATIONS
55	Physician perceptions on probiotics: Italian results of a multinational survey. Digestive and Liver Disease, 2014, 46, e118.	0.4	0
56	The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 506-514.	8.2	5,773
57	Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes. Nature Biotechnology, 2014, 32, 822-828.	9.4	909
58	An integrated catalog of reference genes in the human gut microbiome. Nature Biotechnology, 2014, 32, 834-841.	9.4	1,664
59	Processing faecal samples: a step forward for standards in microbial community analysis. BMC Microbiology, 2014, 14, 112.	1.3	134
60	DOP018 Low microbial diversity in Crohn's disease is due to striking depletion of unknown species. Journal of Crohn's and Colitis, 2014, 8, S23.	0.6	1
61	Probiotic and synbiotic safety in infants under two years of age. Beneficial Microbes, 2014, 5, 45-60.	1.0	66
62	Physician perceptions on probiotics: Results of a multinational survey. Digestive and Liver Disease, 2014, 46, e117-e118.	0.4	2
63	Structure and Functions of the Gut Microbiome. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2014, 14, 290-299.	0.6	19
64	Colonisation by <i><scp>F</scp>aecalibacterium prausnitzii</i> and maintenance of clinical remission in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2013, 38, 151-161.	1.9	181
65	Lactobacillus paracasei and Lactobacillus plantarum strains downregulate proinflammatory genes in an ex vivo system of cultured human colonic mucosa. Genes and Nutrition, 2013, 8, 165-180.	1.2	35
66	Richness of human gut microbiome correlates with metabolic markers. Nature, 2013, 500, 541-546.	13.7	3,641
67	Metagenomic species profiling using universal phylogenetic marker genes. Nature Methods, 2013, 10, 1196-1199.	9.0	442
68	Intestinal Microbiota Composition in Adults. World Review of Nutrition and Dietetics, 2013, , 17-24.	0.1	3
69	Tu2074 Assessment of Digestive Symptoms and Health-Related Quality of Life in Healthy People and Subjects With Irritable Bowel Syndrome: Validation of Symptom Frequency Questionnaire. Gastroenterology, 2013, 144, S-921.	0.6	1
70	An update on the use and investigation of probiotics in health and disease. Gut, 2013, 62, 787-796.	6.1	448
71	Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterology and Motility, 2013, 25, 4-15.	1.6	208
72	Linking the gut microbiota to human health. British Journal of Nutrition, 2013, 109, S21-S26.	1.2	240

#	Article	IF	CITATIONS
73	Phylogenetic Analysis of Dysbiosis in Ulcerative Colitis During Remission. Inflammatory Bowel Diseases, 2013, 19, 481-488.	0.9	285
74	Impacts of prebiotics on the immune system and inflammation. , 2013, , 292-312.		4
75	Hot topics in gut microbiota. United European Gastroenterology Journal, 2013, 1, 311-318.	1.6	50
76	The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes, 2013, 4, 17-27.	4.3	194
77	A Global Perspective on Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2012, 46, 356-366.	1.1	124
78	World Gastroenterology Organisation Global Guidelines. Journal of Clinical Gastroenterology, 2012, 46, 468-481.	1.1	321
79	Mo1170 Flatulence: Is it What it Seems? Clinical, Physiological and Microbiological Features. Gastroenterology, 2012, 142, S-611-S-612.	0.6	5
80	Storage conditions of intestinal microbiota matter in metagenomic analysis. BMC Microbiology, 2012, 12, 158.	1.3	191
81	The gut microbiota in IBD. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 599-608.	8.2	984
82	Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment. Journal of Crohn's and Colitis, 2012, 6, 881-886.	0.6	27
83	Effect of a mixture of inulin and fructo-oligosaccharide on Lactobacillus and Bifidobacterium intestinal microbiota of patients receiving radiotherapy: a randomised, double-blind, placebo-controlled trial. Nutricion Hospitalaria, 2012, 27, 1908-15.	0.2	41
84	The Enteric Microbiota. Colloquium Series on Integrated Systems Physiology From Molecule To Function, 2011, 3, 1-88.	0.3	0
85	Colonization by Faecalibacterium Prausnitzii and Maintenance of Clinical Remission in Patients With Ulcerative Colitis. Gastroenterology, 2011, 140, S-47.	0.6	3
86	International, Prospective, Observational, Multicenter Registry on the Management of Acute Diarrhea in Children (REMAD). Gastroenterology, 2011, 140, S-174-S-175.	0.6	1
87	Probiotic and prebiotic claims in Europe: seeking a clear roadmap. British Journal of Nutrition, 2011, 106, 1765-1767.	1.2	23
88	Enterotypes of the human gut microbiome. Nature, 2011, 473, 174-180.	13.7	5,800
89	Human gut microbiota and its relationship to health and disease. Nutrition Reviews, 2011, 69, 392-403.	2.6	182
90	Transforming growth factorâ€beta type 1 receptor (ALK5) and Smad proteins mediate TIMPâ€1 and collagen synthesis in experimental intestinal fibrosis. Journal of Pathology, 2011, 224, 461-472.	2.1	75

#	Article	IF	CITATIONS
91	Guidelines for the design, conduct and reporting of human intervention studies to evaluate the health benefits of foods. British Journal of Nutrition, 2011, 106, S3-S15.	1.2	95
92	Not all lactic acid bacteria are probiotics, …but some are. British Journal of Nutrition, 2010, 103, 1079-1081.	1.2	54
93	Influence of colectomy on hydrogen excretion in breath. International Journal of Colorectal Disease, 2010, 25, 485-489.	1.0	4
94	A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 2010, 464, 59-65.	13.7	9,342
95	Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. Genome Research, 2010, 20, 1411-1419.	2.4	284
96	Prebiotic effects: metabolic and health benefits. British Journal of Nutrition, 2010, 104, S1-S63.	1.2	1,745
97	Responders and non-responders to probiotic interventions. Gut Microbes, 2010, 1, 200-204.	4.3	59
98	Current level of consensus on probiotic science-Report of an expert meeting- London, 23 November 2009. Gut Microbes, 2010, 1, 436-439.	4.3	89
99	Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life. Journal of Crohn's and Colitis, 2010, 4, 637-641.	0.6	30
100	Inflammatory Disease Processes and Interactions with Nutrition. British Journal of Nutrition, 2009, 101, 1-45.	1.2	346
101	Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflammatory Bowel Diseases, 2009, 15, 275-283.	0.9	125
102	Adhesion properties of Lactobacillus casei strains to resected intestinal fragments and components of the extracellular matrix. Archives of Microbiology, 2009, 191, 153-161.	1.0	85
103	Prepublication data sharing. Nature, 2009, 461, 168-170.	13.7	243
104	Prebiotics, Probiotics and Helminths: The †Natural' Solution?. Digestive Diseases, 2009, 27, 412-417.	0.8	22
105	Faecal DNA and calprotectin as biomarkers of acute intestinal toxicity in patients undergoing pelvic radiotherapy. Alimentary Pharmacology and Therapeutics, 2009, 30, 175-185.	1.9	17
106	M1683 Persistent Effect of Antibiotics On the Intestinal Microbiota. Gastroenterology, 2009, 136, A-410.	0.6	1
107	Probiotics and Chronic Gastrointestinal Disease. , 2009, , 949-975.		2
108	Effects of Probiotic Lactobacillus Casei DN-114 001 in Prevention of Radiation-Induced Diarrhea: Results From Multicenter, Randomized, Placebo-Controlled Nutritional Trial. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1213-1219.	0.4	134

#	Article	IF	CITATIONS
109	What is the role of the enteric commensal flora in IBD?. Inflammatory Bowel Diseases, 2008, 14, S83-S84.	0.9	21
110	Probiotic prophylaxis in predicted severe acute pancreatitis. Lancet, The, 2008, 372, 112-113.	6.3	20
111	The Gut Microbiota Predispose to the Pathophysiology of Acute Postradiotherapy Diarrhea. American Journal of Gastroenterology, 2008, 103, 1754-1761.	0.2	154
112	Unstable Composition of the Fecal Microbiota in Ulcerative Colitis During Clinical Remission. American Journal of Gastroenterology, 2008, 103, 643-648.	0.2	175
113	What is the role of the enteric commensal flora in IBD?. Inflammatory Bowel Diseases, 2008, 14, S83-S84.	0.9	1
114	Prebiotics in Inflammatory Bowel Diseases. , 2008, , 375-392.		0
115	Prebiotics in inflammatory bowel diseases. British Journal of Nutrition, 2007, 98, S85-S89.	1.2	58
116	Studies with Inulin-Type Fructans on Intestinal Infections, Permeability, and Inflammation. Journal of Nutrition, 2007, 137, 2568S-2571S.	1.3	55
117	Hygiene, microbial diversity and immune regulation. Current Opinion in Gastroenterology, 2007, 23, 667-672.	1.0	28
118	Fecal Excretion of Deoxyribonucleic Acid in Long-term Follow-up of Patients with Inactive Ulcerative Colitis. Inflammatory Bowel Diseases, 2007, 13, 386-390.	0.9	11
119	Oral oligofructoseâ€enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Alimentary Pharmacology and Therapeutics, 2007, 25, 1061-1067.	1.9	213
120	Modulatory Effect of Nitric Oxide on Mast Cells During Induction of Dextran Sulfate Sodium Colitis. Digestive Diseases and Sciences, 2007, 52, 45-51.	1.1	8
121	Polyethylene glycol enhances colonic barrier function and ameliorates experimental colitis in rats. International Journal of Colorectal Disease, 2007, 22, 571-580.	1.0	12
122	Mechanisms of Disease: the hygiene hypothesis revisited. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 275-284.	1.7	263
123	Prebiotics and Mucosal Barrier Function. Journal of Nutrition, 2006, 136, 2269-2269.	1.3	4
124	Lactobacillus caseiprevents the upregulation of ICAM-1 expression and leukocyte recruitment in experimental colitis. American Journal of Physiology - Renal Physiology, 2006, 291, G1155-G1162.	1.6	23
125	Enteric Flora in Health and Disease. Digestion, 2006, 73, 5-12.	1.2	207
126	Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. Journal of Leukocyte Biology, 2006, 79, 917-922.	1.5	67

#	Article	IF	CITATIONS
127	Selective Inhibition of Phosphodiesterase-4 Ameliorates Chronic Colitis and Prevents Intestinal Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 940-945.	1.3	38
128	Modulation of the microbial ecology of the human colon by probiotics, prebiotics and synbiotics to enhance human health: An overview of enabling science and potential applications. FEMS Microbiology Ecology, 2005, 52, 145-152.	1.3	289
129	Induction of Colonic Transmural Inflammation by Bacteroides Fragilis. Inflammatory Bowel Diseases, 2005, 11, 99-105.	0.9	18
130	Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut, 2005, 54, 955-959.	6.1	59
131	Inulin and oligofructose: impact on intestinal diseases and disorders. British Journal of Nutrition, 2005, 93, S61-S65.	1.2	76
132	Should yoghurt cultures be considered probiotic?. British Journal of Nutrition, 2005, 93, 783-786.	1.2	258
133	The intestinal flora in inflammatory bowel disease: normal or abnormal?. Current Opinion in Gastroenterology, 2005, 21, 414-8.	1.0	56
134	PASSCLAIM1?Gut health and immunity. European Journal of Nutrition, 2004, 43, ii118-ii173.	1.8	197
135	Fecal excretion of human deoxyribonucleic acid as an index of inflammatory activity in ulcerative colitis. Clinical Gastroenterology and Hepatology, 2004, 2, 683-689.	2.4	13
136	Discussion on toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology, 2004, 127, 366-367.	0.6	27
137	Probiotics and human health: a clinical perspective. Postgraduate Medical Journal, 2004, 80, 516-526.	0.9	233
138	Role of bacteria in experimental colitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 793-804.	1.0	82
139	Relation between epithelial adherence and antiinflammatory action of different lactobacillus strains. Gastroenterology, 2003, 124, A490.	0.6	0
140	Implication of matrix metalloproteinases (MMPs) in transmural inflammation induced by bacteroides fragilis. Gastroenterology, 2003, 124, A322.	0.6	0
141	Fecal human DNA as a marker of intestinal toxicity in patients undergoing abdominal radiotherapy. Gastroenterology, 2003, 124, A146.	0.6	0
142	Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. American Journal of Physiology - Renal Physiology, 2003, 284, G116-G122.	1.6	73
143	Gut flora in health and disease. Lancet, The, 2003, 361, 512-519.	6.3	2,747
144	Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. American Journal of Gastroenterology, 2003, 98, 865-870.	0.2	126

#	Article	IF	CITATIONS
145	The intestine and its microflora are partners for the protection of the host: report on the Danone Symposium "The Intelligent Intestine,―held in Paris, June 14, 2002. American Journal of Clinical Nutrition, 2003, 78, 675-683.	2.2	273
146	Microecology as a target for therapeutic intervention in inflammatory bowel disease. IDrugs: the Investigational Drugs Journal, 2003, 6, 868-73.	0.7	2
147	Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut, 2002, 51, 659-664.	6.1	278
148	Role of microecology in chronic inflammatory bowel diseases. European Journal of Clinical Nutrition, 2002, 56, S34-S38.	1.3	74
149	Increased mucosal TNF-α production in Crohn's disease can be modulated locally by probiotics. Gastroenterology, 2001, 120, A278-A279.	0.6	4
150	Therapeutic Effect of Phenantroline in Two Rat Models of Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology, 2001, 36, 1314-1319.	0.6	30
151	Dietary Inulin Improves Distal Colitis Induced by Dextran Sodium Sulfate in the Rat. American Journal of Gastroenterology, 2001, 96, 1486-1493.	0.2	183
152	Epidermal growth factor increases surface hydrophobicity and resistance to acid in the rat duodenum. American Journal of Physiology - Renal Physiology, 2001, 280, G774-G779.	1.6	13
153	Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut, 2001, 48, 503-507.	6.1	121
154	Surface hydrophobicity of the rat colonic mucosa is a defensive barrier against macromolecules and toxins. Gut, 2000, 46, 515-521.	6.1	64
155	Butyrate enemas in rat colitis induced by dextran sodium sulfate (DSS). Gastroenterology, 2000, 118, A1375.	0.6	0
156	The role of Chinese herbal medicines in a rat model of chronic colitis. Gastroenterology, 2000, 118, A1372.	0.6	3
157	Adherence of Lactobacillus crispatus to colonic epithelium is determined by microenvironmental pH and bacterial metabolic substances. Gastroenterology, 2000, 118, A1342.	0.6	0
158	Inhmition of matrix metalloproteinases(MMPs)prevents tissue injury and fibrotic complications in two rat models of inflammatory bowel disease. Gastroenterology, 2000, 118, A585.	0.6	0
159	Changes in the expression of intestinal proteins during experimental stress. Gastroenterology, 2000, 118, A1133.	0.6	0
160	Laxatives may impair colonic barrier function. Gastroenterology, 2000, 118, A1139.	0.6	0
161	Proteasome independent activation of NFXB in acute stress. Gastroenterology, 2000, 118, A81.	0.6	0
162	Immunomodulatory effect of lactic acid bacteria on human colonic mucosa. Gastroenterology, 2000, 118, A99.	0.6	0

#	Article	IF	CITATIONS
163	Ethanol Feeding Aggravates Morphological and Biochemical Parameters in Experimental Chronic Pancreatitis. Digestion, 1999, 60, 166-174.	1.2	23
164	Derangement of mucosal barrier function by bacteria colonizing the rat colonic mucosa. European Journal of Clinical Investigation, 1998, 28, 1019-1026.	1.7	15
165	Stimulation of transforming growth factor β1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology, 1998, 114, 519-526.	0.6	92
166	Antiinflammatory Effects of Enterically Coated Amoxicillin-Clavulanic Acid in Active Ulcerative Colitis. Inflammatory Bowel Diseases, 1998, 4, 1-5.	0.9	67
167	Stimulation of Mucosal Inflammatory Activity by the Normal Fecal Flora in a Rat Model of Colitis. Inflammatory Bowel Diseases, 1997, 3, 191-197.	0.9	5
168	Deranged hydrophobic barrier of the rat gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs. Gastroenterology, 1997, 112, 1931-1939.	0.6	54
169	Incrimination of anaerobic bacteria in the induction of experimental colitis. American Journal of Physiology - Renal Physiology, 1997, 272, G10-G15.	1.6	56
170	Stimulation of mucosal inflammatory activity by the normal fecal flora in a rat model of colitis. Inflammatory Bowel Diseases, 1997, 3, 191-197.	0.9	5
171	Prescribing nonsteroidal anti-inflammatory drugs together with antisecretory agents is safe but may be useless. Gastroenterology, 1996, 111, 1145-1147.	0.6	5
172	Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Gastroenterology, 1996, 110, 1093-1097.	0.6	58
173	Eicosanoids in Inflammatory Bowel Disease. BioDrugs, 1996, 6, 333-340.	0.7	3
174	Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase. American Journal of Physiology - Renal Physiology, 1996, 270, G425-G430.	1.6	35
175	Induction of Chronic Pancreatic Disease by Trinitrobenzene Sulfonic Acid Infusion into Rat Pancreatic Ducts. Pancreas, 1996, 13, 417-424.	0.5	63
176	Bile acid induced colonic irritation stimulates intracolonic nitric oxide release in humans Gut, 1996, 38, 719-723.	6.1	24
177	Bacterial Peptides Enhance Inflammatory Activity in a Rat Model of Colitis. Digestion, 1996, 57, 368-373.	1.2	7
178	Intracolonic Release <i>in Vivo</i> of Interleukin-1 <i>î²</i> in Chronic Ulcerative Colitis. Clinical Science, 1995, 89, 521-526.	1.8	9
179	Nitric oxide modulates pancreatic basal secretion and response to cerulein in the rat: Effects in acute pancreatitis. Gastroenterology, 1995, 108, 1855-1862.	0.6	85
180	Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology, 1995, 109, 1497-1502.	0.6	121

#	Article	IF	CITATIONS
181	Induction of chronic cholangitis in the rat by trinitrobenzenesulfonic acid. Journal of Hepatology, 1995, 22, 219-225.	1.8	22
182	Phosphatidylcholines as mediators of adaptive cytoprotection of the rat duodenum. Gastroenterology, 1994, 107, 720-727.	0.6	19
183	Role of intestinal microflora in chronic inflammation and ulceration of the rat colon Gut, 1994, 35, 1090-1097.	6.1	109
184	Abnormal leukotriene C4 released by unaffected jejunal mucosa in patients with inactive Crohn's disease Gut, 1994, 35, 517-522.	6.1	19
185	Selective gastric hypersensitivity and reflex hyporeactivity in functional dyspepsia. Gastroenterology, 1994, 107, 1345-1351.	0.6	209
186	Intraluminal Colonic Release of Immunoreactive Tumour Necrosis Factor in Chronic Ulcerative Colitis. Clinical Science, 1994, 87, 453-458.	1.8	34
187	Patients with achalasia lack nitric oxide synthase in the gastroâ€oesophageal junction. European Journal of Clinical Investigation, 1993, 23, 724-728.	1.7	287
188	Regulation of gall bladder motility by the arginine-nitric oxide pathway in guinea pigs Gut, 1993, 34, 911-915.	6.1	45
189	Fate of oral enzymes in pancreatic insufficiency Gut, 1993, 34, 708-712.	6.1	75
190	Influence of dietary fat on duodenal resistance to acid Gut, 1993, 34, 1303-1309.	6.1	10
191	Adaptive cytoprotection of the rat duodenum is not dependent on nitric oxide-induced changes in blood flow. American Journal of Physiology - Renal Physiology, 1993, 264, G994-G1000.	1.6	8
192	The arginine/nitric oxide pathway modulates sphincter of Oddi motor activity in guinea pigs and rabbits. Gastroenterology, 1993, 105, 1299-1305.	0.6	52
193	Duodenal mucosal resistance to intraluminal acid in the rat: Role of adaptive cytoprotection. Gastroenterology, 1992, 102, 1129-1135.	0.6	11
194	Systemic prostacyclin in cirrhotic patients. Gastroenterology, 1992, 102, 303-309.	0.6	53
195	Inhibitors of the lipoxygenase arachidonic acid pathway impair glycocholate efflux in isolated rat hepatocytes. Journal of Hepatology, 1991, 12, 302-311.	1.8	4
196	Antiulcerogenic and antiinflammatory actions of fatty acids on the gastrointestinal tract. Prostaglandins Leukotrienes and Essential Fatty Acids, 1991, 43, 135-140.	1.0	11
197	Enhanced responsiveness to CNS-induced natriuresis in anesthetized nonascitic cirrhotic rats. American Journal of Physiology - Renal Physiology, 1991, 260, C972-C976.	1.6	Ο
198	Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology, 1990, 98, 269-277.	0.6	137

#	Article	IF	CITATIONS
199	Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis Gut, 1990, 31, 539-544.	6.1	173
200	Endotoxin-induced ascites formation in the rat: Partial mediation by platelet-activating factor. Hepatology, 1989, 10, 788-794.	3.6	20
201	Central regulation of gastric acid secretion by paltelet-activating factor in anesthesized rats. Prostaglandins, 1989, 37, 275-285.	1.2	13
202	Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology, 1989, 97, 1294-1299.	0.6	63
203	Reduction by prostacyclin of acetaminophen-induced liver toxicity in the mouse. Hepatology, 1988, 8, 248-253.	3.6	57
204	Longitudinal study of renal prostaglandin excretion in cirrhotic rats: Relationship with the renin–aldosterone system. Clinical Science, 1988, 75, 263-269.	1.8	15
205	Determination of 2,3-dinor-6-ketoprostaglandin F1α in urine samples by liquid chromatography and radioimmunoassay. Biomedical Applications, 1986, 383, 317-324.	1.7	8
206	Cytoprotective effect of prostaglandins on isolated rat liver cells. Liver, 1985, 5, 35-39.	0.1	51
207	Intracerebroventricular Infusion of Sodium Chloride-Rich Artificial Cerebrospinal Fluid in Rats Induces Natriuresis and Releases An Inhibitor of Prostaglandin Synthesis. Clinical Science, 1984, 66, 621-624.	1.8	9
208	Probiotics in Gastrointestinal Diseases. , 0, , 255-269.		0